Patents by Inventor Shaun R. Coughlin
Shaun R. Coughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052042Abstract: The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).Type: ApplicationFiled: December 13, 2021Publication date: February 15, 2024Inventors: Yuichiro ADACHI, Jennifer R. ALLPORT-ANDERSON, Shaun R. COUGHLIN, John Louis DIENER, Lars GADTKE, Felix HARTLEPP, Tiancen HU, Alexander Wolfgang KOCH, Kathrin LADETZKI-BAEHS, Michael John ROMANOWSKI, Cesare RUSSO, Xenia Karola WEZLER, Xiaoling XIE
-
Publication number: 20210403600Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.Type: ApplicationFiled: June 23, 2021Publication date: December 30, 2021Inventors: Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
-
Patent number: 11066481Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.Type: GrantFiled: July 22, 2016Date of Patent: July 20, 2021Assignees: The Regents of the University of California, Pfizer, Inc.Inventors: Thomas Mikita, Lauren K. Ely, Huilan Gao, Yun Kim, Isaac J. Rondon, Tovo David, Shaun R. Coughlin
-
Publication number: 20200095334Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.Type: ApplicationFiled: July 22, 2016Publication date: March 26, 2020Inventors: Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
-
Publication number: 20180216094Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor XI (FXIa) inhibitors in a subject by administering a variant of FXIa.Type: ApplicationFiled: July 22, 2016Publication date: August 2, 2018Inventors: Thomas MIKITA, Lauren K. ELY, Tovo DAVID, Shaun R. COUGHLIN
-
Patent number: 7803560Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: GrantFiled: February 5, 2007Date of Patent: September 28, 2010Assignee: The Regents of the University of CaliforniaInventors: Israel F. Charo, Shaun R. Coughlin
-
Publication number: 20090123938Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: ApplicationFiled: February 5, 2007Publication date: May 14, 2009Applicant: The Regents of the University of CaliforniaInventors: Israel R. Charo, Shaun R. Coughlin
-
Patent number: 7176283Abstract: Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis.Type: GrantFiled: December 8, 1998Date of Patent: February 13, 2007Assignee: The Regents of the University of CaliforniaInventors: Shaun R. Coughlin, Hiroaki Ishihara, Andrew Connolly
-
Patent number: 7119182Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.Type: GrantFiled: June 7, 1995Date of Patent: October 10, 2006Assignee: The Regents of the University of CaliforniaInventors: Shaun R. Coughlin, Robert M. Scarborough
-
Patent number: 7105641Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: GrantFiled: March 1, 2004Date of Patent: September 12, 2006Assignee: The Regents of the University of CaliforniaInventors: Israel R. Charo, Shaun R. Coughlin
-
Publication number: 20040223968Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: ApplicationFiled: March 1, 2004Publication date: November 11, 2004Applicant: The Regents of the University of CaliforniaInventors: Israel R. Charo, Shaun R. Coughlin
-
Publication number: 20040219644Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: ApplicationFiled: March 1, 2004Publication date: November 4, 2004Applicant: The Regents of the University of CaliforniaInventors: Israel R. Charo, Shaun R. Coughlin
-
Patent number: 6730301Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.Type: GrantFiled: July 25, 2000Date of Patent: May 4, 2004Assignee: The Regents of the University of CaliforniaInventors: Israel R. Charo, Shaun R. Coughlin
-
Publication number: 20020127702Abstract: Method and compositions for regulating cell cycle progression are disclosed. Compositions include nucleic acids comprising a human Cdc5 gene, antisense gene and fragments thereof and a human Cdc5 protein and polypeptide fragments thereof polypeptide. The consensus DNA binding site for hCdc5 has been described.Type: ApplicationFiled: January 8, 2001Publication date: September 12, 2002Inventors: Harold S. Bernstein, Shaun R. Coughlin
-
Patent number: 6197541Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.Type: GrantFiled: February 17, 1993Date of Patent: March 6, 2001Assignees: COR Therapeutics, Inc., Regents of the University of CaliforniaInventor: Shaun R. Coughlin
-
Patent number: 6183961Abstract: Method and compositions for regulating cell cycle progression are disclosed. Compositions include nucleic acids comprising a human Cdc5 gene, antisense gene and fragments thereof and a human Cdc5 protein and polypeptide fragments thereof polypeptide. The compositions can be used in a method to treat diseases relating to a cell cycle defect.Type: GrantFiled: September 18, 1998Date of Patent: February 6, 2001Assignee: The Regents of the University of CaliforniaInventors: Harold S. Bernstein, Shaun R. Coughlin
-
Patent number: 6132987Abstract: DNAs encoding receptors for the chemokine, Monocyte Chemotactic Protein-1 (MCP-1), are disclosed. Recombinant reagents and methods for expressing the DNAs are also provided. Exemplary receptor proteins are MCP-1RA and MCP-1RB, which correspond to alternatively spliced transcripts of the human MCP-1R gene. The receptor proteins of the invention are useful in assays to identify agonists and antagonists of MCP-1.Type: GrantFiled: May 25, 1995Date of Patent: October 17, 2000Assignee: The Regents of the University of CaliforniaInventors: Israel F. Charo, Shaun R. Coughlin
-
Patent number: 6124101Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignees: The Regent of the University of California, COR Therapeutics, Inc.Inventor: Shaun R. Coughlin
-
Patent number: 6024936Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.Type: GrantFiled: June 7, 1995Date of Patent: February 15, 2000Assignees: The Regents of the University of California, COR Therapeutics, Inc.Inventors: Shaun R. Coughlin, Robert M. Scarborough
-
Patent number: 5925529Abstract: This invention relates to peptide ligand discovery and is particularly directed to a method for the discovery of agonists for membrane bound receptors. The inventive detection system involves the use of a "tethered" ligand for probing receptor binding. The general detection system includes a membrane, a membrane bound receptor, and a chimeric ligand presenting molecule. This chimeric protein forms the tethered ligand and in turn includes a membrane domain, a linker domain, a ligand domain, and a cleavable terminal domain. The "ligands" of the system are exposed by the addition of a specific peptidase that cleaves at the designated sequence. The sequence of the ligand that produces signal as a result of the interaction between the agonist and receptor can be then be isolated using sib selection.Type: GrantFiled: June 7, 1995Date of Patent: July 20, 1999Assignee: The Regents of the University of CaliforniaInventors: Shaun R. Coughlin, Ji Chen, Harold Bernstein, Maki Ishii, Ling Wang, Mian Chen